SEALS Second DSMB Positive Review

📢Second DSMB review completed: Confirmation of a satisfactory safety and tolerability profile for NX210c Axoltis Pharma is pleased to announce that the Data Safety Monitoring Board (DSMB) has completed its second safety review of a cohort of the first 50 patients of the SEALS study and confirmed a good safety profile of NX210c. SEALS is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to assess whether NX210c, administered intravenously, may offer a novel therapeutic approach in ALS, a neurodegenerative disease with high unmet need. NX210c is a promising therapeutic peptide directed at blood brain barrier restoration, neuroprotection and enhanced neurotransmission. Patient enrollment in the SEALS trial was completed in November 2025, reflecting strong patient and provider engagement across participating sites. Topline results expected Q2 2026 represent a key upcoming milestone for NX210c and Axoltis Pharma’s ALS development program. LinkedIn Axoltis 60 avenue Rockefeller, 69008 Lyon, France © 2026 Axoltis. All rights reserved. Disclaimer : NX210c is a drug candidate currently in a Phase 2 clinical trial for ALS and is not yet approved for commercialization. Legal Notice

The release as fetched from its publisher. axoltis.com ↗